|
FUSION II
Follow-Up Serial Infusions Of Nesiritide II
Ongoing trial
 |
Author(s) |
Yancy CW, Krum H, Massie BM, Silver MA, Stevenson LW, Cheng M, Kim SS, Evans R |
 |
Title(s) |
The second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design |
|
Reference(s) |
Am Heart J 2007;153:478–84 |
|
Disease |
Chronic heart failure |
|
Purpose |
To assess the efficacy, safety and optimal dosing frequency of nesiritide in patients with advanced heart failure |
|
Study design |
Randomised, double-blind, placebo-controlled, parallel-group |
|
Follow-up |
Aim 24 weeks |
|
Patients |
Aim 900, aged ≥ 18 years, with heart failure NYHA class III or IV, left ventricular ejection fraction < 40% and ≥ 2 hospitalisations for chronic decompensated heart failure within the preceding 12 months (at least one within the preceding 5–60 days) |
|
Treatment regimen |
Nesiritide, 2 μg/kg iv bolus, then 0.01 μg/kg/min for 4–6 h, once or twice weekly, or placebo |
|
Results |
Not yet available |
|
|
|
